Role of Coenzyme Q10 in Chronic Kidney Disease

Launched by TANTA UNIVERSITY · Jul 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Coenzyme Q10, a natural substance that helps produce energy in cells, on patients with chronic kidney disease (CKD) who are not on dialysis. The trial involves 44 participants who have CKD stages 2 to 3b and are newly diagnosed with high blood pressure. The goal is to see if adding Coenzyme Q10 to their usual treatment with a medication called ramipril can help lower blood pressure, reduce protein in urine, and improve bone health over six months.

To be eligible, participants must be at least 18 years old and have specific kidney function measurements, along with a certain level of protein in their urine and normal potassium levels. People with certain health conditions, like diabetes or heart disease, and those taking specific medications will not be allowed to join the study. Participants will be randomly assigned to one of two groups: one will receive the usual medication with a placebo (an inactive pill), while the other will get the medication and Coenzyme Q10. Throughout the study, participants will have regular check-ins to monitor their health and adherence to the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old.
• • Both sexes.
• • Patients matched in the duration of CKD.
• • Non-dialysis chronic kidney disease (CKD) patient with estimated glomerular filtration rate (GFR) 30-89 mL/min/1.73m2 (Stage 2-3b).
• • Patients with albumin-to-creatinine ratio ≥ 30 mg/g.
• • Patients with serum Potassium \< 5 mEq/L.
• • A newly diagnosed patients with hypertension.
• Exclusion criteria:
• • Patients with elevated level of potassium ≥ 5 mEq/L.
• • Patients with diabetes.
• • Patients with cancer.
• • Patients with heart disease.
• • Patients with hepato-biliary disease and other liver diseases.
• • Patients with kidney stones and urinary tract infection.
• • Patients with an overactive thyroid gland.
• • Patients with bleeding disorder.
• • History of drug allergy to ACEI or ARBs.
• • Pregnant and breastfeeding women.
• • Patients with blood pressure ≥180/110 or \<100/60.
• • Patients on alteplase, azothiopurine, everolimus, sirolimus, lithium, non-steroidal anti-inflammatory drugs (epifenac, tenoxicam, Celecoxib....), potassium retentive diuretics (amiloride, spironolactone), other ACEIs and ARBs will be excluded to avoid possible drug-drug interactions with ramipril.
• • Patients on omega-3 fatty acids; vitamins (especially A, C, E, K), Chemotherapy and oral anticoagulant (warfarin), cholestyramine, orlistate will be excluded to avoid possible drug interactions that could affect Coenzyme Q10